Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2017-2021 - Product Image

Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2017-2021

  • ID: 4032444
  • Report
  • Region: Global
  • 77 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Acacia Pharma
  • Eisai
  • Helsinn
  • Midatech Pharma
  • OPKO Health
  • Solasia Pharma K.K
  • MORE
About CINV Drugs

The launch of extended half-life drugs in the market is expected to substantially improve the adoption rates, owing to their ability to act for prolonged periods of time. For instance, Heron Therapeutics' SUSTOL and Tesaro's VARUBI offer protection against CINV for five days and seven days, respectively. Additionally, the emergence of oral therapies is expected to enhance the patient compliance, resulting in market growth.

Analysts forecast the global CINV drugs market to grow at a CAGR of 5.41% during the period 2017-2021.

Covered in this Report:

The report covers the present scenario and the growth prospects of the global CINV drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of CINV drugs.

The Market is Divided Into the Following Segments Based on Geography:

Americas
APAC
EMEA

Global Thoracic Surgery Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years.

The report also includes a a discussion of the key vendors operating in this market.

Key Vendors:

GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro

Other Prominent Vendors:

Acacia Pharma
Aphios
Baxter Healthcare
Dr. Reddy's Laboratories
Eisai
Especificos Stendhal
F. Hoffmann-La Roche
Kyowa Hakko Kirin
Lee’s Pharmaceutical Holdings
Midatech Pharma
Mundipharma
Mylan
Ono Pharmaceutical
OPKO Health
Orchid Chemicals & Pharmaceuticals
Otsuka Pharmaceutical
Purdue Pharma
Sandoz (a subsidiary of Novartis)
SciClone Pharmaceuticals
Shin Nippon Biomedical Laboratories
Solasia Pharma K.K.
Specialised Therapeutics
Sun Pharma
Taiho Pharmaceutical
Teva Pharmaceuticals

Market Drivers:

Growing preference of chemotherapy drugs in developing countries
For a full, detailed list, view the full report

Market Challenges:

Growing popularity of alternate therapies for the treatment of cancer in developed countries
For a full, detailed list, view the full report

Market Trends:

Increasing inorganic growth strategies likely to fuel the market growth
For a full, detailed list, view the full report

Key Questions Answered in this Report:
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acacia Pharma
  • Eisai
  • Helsinn
  • Midatech Pharma
  • OPKO Health
  • Solasia Pharma K.K
  • MORE
Part 01: Executive summary

Part 02: Scope of the report
Market overview
Top-vendor offerings

Part 03: Market research methodology
Research methodology
Economic indicators

Part 04: Introduction
Key market highlights
Highlights

Part 05: Disease overview
Understanding the disease
Pathophysiology
Central pathway
Peripheral pathway
Management of disease

Part 06: Pipeline analysis

Part 07: Market landscape
Global CINV drugs market
Five forces analysis

Part 08: Market segmentation by therapy
Serotonin receptor antagonists
NK1 receptor antoagonists
Others

Part 09: Geographical segmentation
CINV drugs market in Americas
CINV drugs market in EMEA
CINV drugs market in APAC

Part 10: Market drivers
Growing cancer population driving the market growth
Growing preference for chemotherapy drugs in developing countries
Approval of new drugs fuels the market growth

Part 11: Impact of drivers

Part 12: Market challenges
Growing popularity of alternate therapies for the treatment of cancer in developed countries
Loss of patent exclusivities increasing generic competition
Limitations in existing therapies hindering the growth prospects

Part 13: Impact of drivers and challenges

Part 14: Market trends
Robust R&D activities fueling the pipeline
Increasing inorganic growth strategies likely to fuel the market growth
Novel treatment options coupled with new applications

Part 15: Vendor landscape
Competitive scenario

Part 16: Key vendor analysis
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro
Other prominent vendors

Part 17: Appendix
List of abbreviations

Part 18: Extras

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Pipeline landscape
Exhibit 03: Key pipeline candidates
Exhibit 04: Global CINV drugs market snapshot
Exhibit 05: Analysis of global CINV drugs market
Exhibit 06: Global CINV drugs market 2016-2021 ($ billions)
Exhibit 07: Key initiatives in emerging economies
Exhibit 08: Opportunity analysis of global CINV drugs market
Exhibit 09: Opportunity analysis in developed and emerging markets
Exhibit 10: Five forces analysis
Exhibit 11: Segmentation of global CINV drugs market by therapy 2016 (% share)
Exhibit 12: Lifecycle analysis of segments in global CINV drugs market
Exhibit 13: Geographic segmentation by revenue 2016 and 2021
Exhibit 14: Geographic segmentation by revenue 2016 ($ millions)
Exhibit 15: Market scenario in Americas
Exhibit 16: CINV drugs market in Americas 2016-2021 ($ millions)
Exhibit 17: Market scenario in EMEA
Exhibit 18: CINV drugs market in EMEA 2016-2021 ($ millions)
Exhibit 19: Market scenario in APAC
Exhibit 20: CINV drugs market in APAC 2016-2021 ($ millions)
Exhibit 21: Key drivers and challenges in APAC
Exhibit 22: Top ten cancers in the US in 2013
Exhibit 23: Key approvals in the market in 2015 and 2016
Exhibit 24: Impact of drivers
Exhibit 25: Merck: YoY revenue and growth rate of EMEND 2013-2015 ($ millions)
Exhibit 26: Forcefield analysis of drivers and challenges
Exhibit 27: Impact of drivers and challenges
Exhibit 28: Key vendors that are extensively conducting R&D activities
Exhibit 29: Competitive structure analysis of global CINV drugs market 2015
Exhibit 30: Market share analysis in global CINV drugs market
Exhibit 31: Competitive analysis of global CINV drugs market
Exhibit 32: Market penetration of various global CINV drugs manufacturers 2015
Exhibit 33: GlaxoSmithKline: Strength assessment
Exhibit 34: GlaxoSmithKline: Strategy assessment
Exhibit 35: GlaxoSmithKline: Opportunity assessment
Exhibit 36: Helsinn: Key highlights
Exhibit 37: Helsinn: Strength assessment
Exhibit 38: Helsinn: Strategy assessment
Exhibit 39: Helsinn: Opportunity assessment
Exhibit 40: Heron Therapeutics: Key highlights
Exhibit 41: Heron Therapeutics: Strength assessment
Exhibit 42: Heron Therapeutics strategy assessment
Exhibit 43: Heron Therapeutics: Opportunity assessment
Exhibit 44: Merck: Key highlights
Exhibit 45: Merck: strength assessment
Exhibit 46: Merck: Strategy assessment
Exhibit 47: Merck: Opportunity assessment
Exhibit 48: Merck: YoY revenue and growth rate of EMEND 2013-2015 ($ millions)
Exhibit 49: Tesaro: Key highlights
Exhibit 50: Tesaro: Strength assessment
Exhibit 51: Tesaro: Strategy assessment
Exhibit 52: Tesaro: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Acacia Pharma
  • Eisai
  • Helsinn
  • Midatech Pharma
  • OPKO Health
  • Solasia Pharma K.K
  • MORE
Global CINV Drugs Market 2017-2021

Key players in the global CINV drugs market: GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck, and Tesaro

Other Prominent Vendors in the market are: Acacia Pharma, Aphios, Baxter Healthcare, Dr. Reddy's Laboratories, Eisai, Especificos Stendhal, F. Hoffmann-La Roche, Kyowa Hakko Kirin, Lee’s Pharmaceutical Holdings, Midatech Pharma, Mundipharma, Mylan, Ono Pharmaceutical, OPKO Health, Orchid Chemicals & Pharmaceuticals, Otsuka Pharmaceutical, Purdue Pharma, Sandoz (a subsidiary of Novartis), SciClone Pharmaceuticals, Shin Nippon Biomedical Laboratories, Solasia Pharma K.K., Specialised Therapeutics, Sun Pharma, Taiho Pharmaceutical, and Teva Pharmaceuticals

Commenting on the report, an analyst said: “The high unmet medical need in the market has driven the R&D activities of existing as well as new vendors. Helsinn is one of the leading companies that has a strong pipeline of CINV drugs with two drug candidates in Phase III and Phase I stages. Helsinn has collaborated with Taiho Pharmaceutical for the development and commercialization of netupitant IV in Japan. Heron Therapeutics is developing HTX-019, currently in Phase I stage, for the prevention and treatment of CINV. In addition, new vendors such as Shin Nippon Biomedical Laboratories and Acacia Pharma are aggressively advancing their pipeline to launch new drugs during the forecast period. Shin Nippon Biomedical Laboratories and Acacia are developing granisetron intranasal and APD403, respectively. Both these drugs are in Phase II development stage. These pipeline drugs are expected to gain approval during the forecast period and will likely fuel the market growth.”

According to the report, the high unmet medical need in the market has driven the R&D activities of existing as well as new vendors. Helsinn is one of the leading companies that has a strong pipeline of CINV drugs with two drug candidates in Phase III and Phase I stages. Helsinn has collaborated with Taiho Pharmaceutical for the development and commercialization of netupitant IV in Japan. Heron Therapeutics is developing HTX-019, currently in Phase I stage, for the prevention and treatment of CINV. In addition, new vendors such as Shin Nippon Biomedical Laboratories and Acacia Pharma are aggressively advancing their pipeline to launch new drugs during the forecast period. Shin Nippon Biomedical Laboratories and Acacia are developing granisetron intranasal and APD403, respectively. Both these drugs are in Phase II development stage. These pipeline drugs are expected to gain approval during the forecast period and will likely fuel the market growth.

Further, the report states that patent expiries result in the loss of market exclusivity of a drug, which will result in a rapid decline in its sales. This will further lead to the market entry of cost-effective generic versions that have a similar efficacy and safety profile as the branded therapy. The patents of majority of the CINV therapeutics have either expired or are set to expire at the end of the forecast period. For instance, Zofran by GlaxoSmithKline lost its patent exclusivity in 2005 and Kytril by F. Hoffmann-La Roche in 2007. This led to the market entry of their generics, reducing their sales. Similarly, EMEND by Merck and Aloxi by Helsinn lost their patent exclusivities in April 2015, leading to the availability of their generics in the market. EMEND reported a YoY decline of 3.3% owing to patent expiry covering product's oral dosage form in 2015. Therefore, loss of patent expiries will substantially impact the market growth.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • GlaxoSmithKline
  • Helsinn
  • Heron Therapeutics
  • Merck
  • Tesaro
  • Acacia Pharma
  • Aphios
  • Baxter Healthcare
  • Dr. Reddy's Laboratories
  • Eisai
  • Especificos Stendhal
  • F. Hoffmann-La Roche
  • Kyowa Hakko Kirin
  • Lee’s Pharmaceutical Holdings
  • Midatech Pharma
  • Mundipharma
  • Mylan
  • Ono Pharmaceutical
  • OPKO Health
  • Orchid Chemicals & Pharmaceuticals
  • Otsuka Pharmaceutical
  • Purdue Pharma
  • Sandoz (a subsidiary of Novartis)
  • SciClone Pharmaceuticals
  • Shin Nippon Biomedical Laboratories
  • Solasia Pharma K.K
  • Specialised Therapeutics
  • Sun Pharma
  • Taiho Pharmaceutical
  • Teva Pharmaceuticals
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll